We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
President Trump's recent decision to delay the implementation of tariffs on goods from the European Union till July 9 has been well received by markets. Trump has delayed his decision to impose 50% tariffs on EU imports from June 1 to allow talks between Washington and the EU with the objective of arriving at a deal.
Another encouraging development was the surge in May consumer confidence. The primary driver of the increase was the progress in U.S.-China trade negotiations, with President Trump deciding earlier in the month to halt severe tariffs. In this reassuring scenario, keeping an eye on broker-favorite stocks like Beyond (BYON - Free Report) , BrightSpring Health Services (BTSG - Free Report) , Air Canada (ACDVF - Free Report) , Emergent BioSolutions (EBS - Free Report) and Adient Plc (ADNT - Free Report) appears prudent.
We have designed a screen to shortlist stocks based on improving broker recommendations and upward revisions in earnings estimates over the past four weeks. Also, since the price/sales ratio is a strong complementary valuation metric in the presence of broker information, it has been included. The price/sales ratio takes care of the company’s top line, making the strategy a well-rounded one.
Screening Criteria
# (Up- Down Rating)/ Total (4 weeks) =Top #75 (This gives the list of top 75 companies that have witnessed net upgrades over the last 4 weeks).
% change in Q (1) est. (4 weeks) = Top #10 (This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter).
Price-to-Sales = Bot%10 (The lower the ratio, the better. Companies meeting this criterion are in the bottom 10% of our universe of over 7,700 stocks with respect to this ratio).
Price greater than 5 (as a stock trading below $5 will not likely create significant interest for most of the investors).
Average Daily Volume greater than 100,000 shares over the last 20 trading days (Volume has to be significant to ensure that these are easily traded).
Market value ($ mil) = Top #3000 (This gives us stocks that are the top 3000 in terms of market capitalization).
Com/ADR/Canadian= Com (This eliminates the ADR and Canadian stocks).
Here are five of the 10 stocks that made it through the screen:
Beyond, based in Murray, UT, is an e-commerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands. The company offers a comprehensive array of products and services that enable its customers to enhance their daily lives.
BYON beat the Zacks Consensus Estimate for earnings in two of the trailing four quarters, missing the mark in the other two. The average beat is 3.7%. Beyond currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
BrightSpring provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through its service lines, including pharmacy, home health care and primary care, rehabilitation, and behavioral health, the company provides comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.
BrightSpring’s 2025 earnings growth rate is pegged at 82.1%. The Zacks Consensus Estimate for BTSG’s 2025 revenues indicates a rise of 9.1% from 2024’s actuals. The stock carries a Zacks Rank #2 currently.
Air Canada has been benefiting from the impressive scenario in air travel demand. Low fuel costs represent another tailwind. The Zacks Consensus Estimate for 2026 sales and earnings has increased 5.6% and 25.7%, respectively, on a year-over-year basis.
The Zacks Consensus Estimate for current-year earnings has increased 2.1% over the past seven days. ACDVF currently carries a Zacks Rank #3 (Hold).
Emergent BioSolutions derives a substantial portion of its revenues from the sales of its anthrax and smallpox vaccines to the U.S. government, which the latter procures for the strategic national stockpile. These procurements are done under fixed-term contracts. Any loss of existing contracts or failure to get new or follow-on contracts may significantly hurt the company’s prospects.
EBS beat the Zacks Consensus Estimate for earnings in three of the trailing four quarters, missing the mark in the other quarter. The average beat was 49.9%. Emergent BioSolutions currently carries a Zacks Rank of 3.
Dublin, Ireland-based Adient is one of the world’s largest automotive seating suppliers. Adient has been gaining customers with its broad range of products. A diverse customer base and international presence have helped the company create a strong market position.
ADNT beat the Zacks Consensus Estimate for earnings in three of the trailing four quarters, missing the mark in the other quarter. The average beat is 18.3%. Adient currently carries a Zacks Rank of 3.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Image: Bigstock
5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost
President Trump's recent decision to delay the implementation of tariffs on goods from the European Union till July 9 has been well received by markets. Trump has delayed his decision to impose 50% tariffs on EU imports from June 1 to allow talks between Washington and the EU with the objective of arriving at a deal.
Another encouraging development was the surge in May consumer confidence. The primary driver of the increase was the progress in U.S.-China trade negotiations, with President Trump deciding earlier in the month to halt severe tariffs. In this reassuring scenario, keeping an eye on broker-favorite stocks like Beyond (BYON - Free Report) , BrightSpring Health Services (BTSG - Free Report) , Air Canada (ACDVF - Free Report) , Emergent BioSolutions (EBS - Free Report) and Adient Plc (ADNT - Free Report) appears prudent.
We have designed a screen to shortlist stocks based on improving broker recommendations and upward revisions in earnings estimates over the past four weeks. Also, since the price/sales ratio is a strong complementary valuation metric in the presence of broker information, it has been included. The price/sales ratio takes care of the company’s top line, making the strategy a well-rounded one.
Screening Criteria
# (Up- Down Rating)/ Total (4 weeks) =Top #75 (This gives the list of top 75 companies that have witnessed net upgrades over the last 4 weeks).
% change in Q (1) est. (4 weeks) = Top #10 (This gives the top 10 stocks that have witnessed earnings estimate revisions over the past 4 weeks for the upcoming quarter).
Price-to-Sales = Bot%10 (The lower the ratio, the better. Companies meeting this criterion are in the bottom 10% of our universe of over 7,700 stocks with respect to this ratio).
Price greater than 5 (as a stock trading below $5 will not likely create significant interest for most of the investors).
Average Daily Volume greater than 100,000 shares over the last 20 trading days (Volume has to be significant to ensure that these are easily traded).
Market value ($ mil) = Top #3000 (This gives us stocks that are the top 3000 in terms of market capitalization).
Com/ADR/Canadian= Com (This eliminates the ADR and Canadian stocks).
Here are five of the 10 stocks that made it through the screen:
Beyond, based in Murray, UT, is an e-commerce-focused retailer with an affinity model that owns or has ownership interests in various retail brands. The company offers a comprehensive array of products and services that enable its customers to enhance their daily lives.
BYON beat the Zacks Consensus Estimate for earnings in two of the trailing four quarters, missing the mark in the other two. The average beat is 3.7%. Beyond currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
BrightSpring provides complementary and integrated home- and community-based pharmacy and health solutions for complex populations in need of specialized and/or chronic care. Through its service lines, including pharmacy, home health care and primary care, rehabilitation, and behavioral health, the company provides comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.
BrightSpring’s 2025 earnings growth rate is pegged at 82.1%. The Zacks Consensus Estimate for BTSG’s 2025 revenues indicates a rise of 9.1% from 2024’s actuals. The stock carries a Zacks Rank #2 currently.
Air Canada has been benefiting from the impressive scenario in air travel demand. Low fuel costs represent another tailwind. The Zacks Consensus Estimate for 2026 sales and earnings has increased 5.6% and 25.7%, respectively, on a year-over-year basis.
The Zacks Consensus Estimate for current-year earnings has increased 2.1% over the past seven days. ACDVF currently carries a Zacks Rank #3 (Hold).
Emergent BioSolutions derives a substantial portion of its revenues from the sales of its anthrax and smallpox vaccines to the U.S. government, which the latter procures for the strategic national stockpile. These procurements are done under fixed-term contracts. Any loss of existing contracts or failure to get new or follow-on contracts may significantly hurt the company’s prospects.
EBS beat the Zacks Consensus Estimate for earnings in three of the trailing four quarters, missing the mark in the other quarter. The average beat was 49.9%. Emergent BioSolutions currently carries a Zacks Rank of 3.
Dublin, Ireland-based Adient is one of the world’s largest automotive seating suppliers. Adient has been gaining customers with its broad range of products. A diverse customer base and international presence have helped the company create a strong market position.
ADNT beat the Zacks Consensus Estimate for earnings in three of the trailing four quarters, missing the mark in the other quarter. The average beat is 18.3%. Adient currently carries a Zacks Rank of 3.
You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial to the Research Wizard today.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
Disclosure: Performance information for Zacks’ portfolios and strategies are available at: https://www.zacks.com/performance.